Gregory A Demopulos

Entity type image
Type: Person
Name: Gregory A Demopulos
First reported May 22 2013 - Updated May 22 2013 - 1 reports
Omeros Corp
Omeros Corp

Omeros to Present at Two Upcoming Conferences

Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today announced that Gregory A. Demopulos, ... [Published Zecco - May 22 2013]

More Content

All (20) | News (18) | Reports (0) | Blogs (0) | Audio/Video (0) | Fact Sheets (0) | Press Releases (2)
sort by: Date | Relevance
Omeros gets European regulatory nod to beign ph... [Published PharmaBiz - Jun 15 2013]
OMEROS CORPORATION : Omeros Obtains Regulatory ... [Published 4 Traders - Jun 13 2013]
Omeros' IND for Huntington's disease drug recei... [Published Individual.com - Jun 10 2013]
Omeros announces positive results from Phase I ... [Published Individual.com - Jun 05 2013]
6/3/13 - Investigational New Drug Application C... [Published Pharmacy Choice - Jun 03 2013]
Omeros Reports Positive Results from OMS824 Pos... [Published KGWN TV - May 31 2013]
Omeros Files Clinical Trial Application for Lea... [Published TickerTech.com - May 28 2013]
Omeros Announces INDA for OMS824 Cleared by FDA... [Published BioMedReports - May 24 2013]
Omeros Announces INDA for OMS824 in Huntingtons... [Published Equities.com - May 23 2013]
Investigational New Drug Application Cleared By... [Published TheStreet.com - May 23 2013]
Omeros to Present at Two Upcoming Conferences [Published Zecco - May 22 2013]
Omeros seeks orphan drug status from US FDA for... [Published PharmaBiz - Apr 19 2013]
Omeros Announces that GPR17 Antagonists Improve... [Published PR Newswire - Apr 10 2013]
Omeros Announces Toxicology Study Data from MAS... [Published PR Newswire - Feb 07 2013]
Omeros announces positive phase III trial resul... [Published PharmaBiz - Dec 29 2012]
Omeros reports positive data from phase I trial... [Published PharmaBiz - Dec 10 2012]
Omeros' announces positive phase 3 trial result... [Published PharmaBiz - Nov 07 2012]
Omeros begins enrollment in phase I trial evalu... [Published PharmaBiz - Nov 03 2012]
Omeros enrolls last patient in OMS302's 2nd pha... [Published PharmaBiz - Oct 05 2012]
Omeros files IND application with US FDA for le... [Published PharmaBiz - Sep 08 2012]
1
In Focus
  •  
Jeffrey Black, Vikas Sinha, Harvey J. Berger
  •  
Omeros Corp, Celgene Corporation, Deutsche Bank AG, [more]
  •  
FDA Food & Drug Administration, US Securities and Exchange Commission, European Medicines Agency, [more]
  •  
Huntington's Disease, Phase I, Clinical trials, [more]
  •  
OMS302, OMS103HP, PharmacoSurgery, [more]
  •  
Seattle, Boston (Massachusetts, United States), Chicago, [more]
  •  
United States, Israel, Italy
  •  
Diseases, Medication, Research & Development, [more]
  •  
Health, Pharma & Biotech
PharmaBiz, Individual.com, Zecco, [more]
Content Volume
Document Volume
Network
Network

Press Releases

sort by: Date | Relevance
Omeros Announces that GPR17 Antagonists Improve... [Published PR Newswire - Apr 10 2013]
Omeros Announces Toxicology Study Data from MAS... [Published PR Newswire - Feb 07 2013]
1
About
Silobreaker
Press Room
Products
Online Service
On-Premises Software
Contact Us
Sales
Support
Legal
Terms of Use
Privacy Policy


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2013 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.